IDH2 and glioma: demonstrated that restoration of STAT1 with IDH-C35 reversed the reduction in CXCL10 and T cell accumulation, when combined with the vaccine, it could enhance anti-tumor immune function and the performance of peptide vaccines and improve asymptomatic survival of IDH-mutant glioma patients (13, 78).